Nevro Corp (NYSE:NVRO) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in Nevro Corp (NYSE:NVRO) by 82.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,556 shares of the medical equipment provider’s stock after selling 41,609 shares during the quarter. SG Americas Securities LLC’s holdings in Nevro were worth $535,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Advisor Group Inc. grew its position in shares of Nevro by 64.5% in the 4th quarter. Advisor Group Inc. now owns 921 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 361 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Nevro by 3.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 15,679 shares of the medical equipment provider’s stock valued at $610,000 after purchasing an additional 525 shares during the last quarter. Bellevue Group AG boosted its stake in Nevro by 1.3% during the 4th quarter. Bellevue Group AG now owns 81,438 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 1,023 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Nevro in the 4th quarter worth about $113,000. Finally, Legal & General Group Plc grew its position in Nevro by 31.2% in the 4th quarter. Legal & General Group Plc now owns 12,886 shares of the medical equipment provider’s stock worth $502,000 after purchasing an additional 3,065 shares during the last quarter.

In other Nevro news, Director Elizabeth H. Weatherman purchased 2,460 shares of the stock in a transaction dated Friday, June 7th. The shares were bought at an average cost of $60.99 per share, with a total value of $150,035.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin C. Oboyle purchased 1,675 shares of the stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average cost of $60.00 per share, for a total transaction of $100,500.00. The disclosure for this purchase can be found here. Company insiders own 7.60% of the company’s stock.

A number of equities analysts have issued reports on the company. Morgan Stanley decreased their price target on Nevro from $70.00 to $64.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. JMP Securities reduced their price objective on Nevro from $80.00 to $70.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. Canaccord Genuity lowered Nevro from a “buy” rating to a “hold” rating and reduced their target price for the company from $62.00 to $50.00 in a report on Friday, May 10th. ValuEngine upgraded Nevro from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, Zacks Investment Research upgraded Nevro from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 14th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $57.83.

Shares of NYSE:NVRO traded down $0.59 during midday trading on Friday, hitting $62.90. 312,163 shares of the stock were exchanged, compared to its average volume of 645,079. The company has a current ratio of 6.30, a quick ratio of 4.87 and a debt-to-equity ratio of 0.83. Nevro Corp has a 52-week low of $34.75 and a 52-week high of $86.75. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -38.35 and a beta of 0.24.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($1.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.79). The firm had revenue of $82.10 million for the quarter, compared to analysts’ expectations of $87.47 million. Nevro had a negative return on equity of 31.84% and a negative net margin of 19.79%. Nevro’s revenue was down 6.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.59) earnings per share. On average, sell-side analysts forecast that Nevro Corp will post -3.83 EPS for the current year.

WARNING: This news story was first posted by Rockland Register and is owned by of Rockland Register. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://rocklandregister.com/2019/06/14/nevro-corp-nvro-holdings-lowered-by-sg-americas-securities-llc.html.

Nevro Company Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Recommended Story: Depreciation

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.